ADC Therapeutics SA (ADCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ADC Therapeutics SA (ADCT) has a cash flow conversion efficiency ratio of 0.137x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.71 Million) by net assets ($-216.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of ADC Therapeutics SA to measure how much of total assets are equity-financed.
ADC Therapeutics SA - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how ADC Therapeutics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does ADC Therapeutics SA reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
ADC Therapeutics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ADC Therapeutics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GR Silver Mining Ltd
V:GRSL
|
-0.097x |
|
Ice Make Refrigeration Limited
NSE:ICEMAKE
|
-0.437x |
|
MEDIFAST INC
NYSE:MED
|
0.001x |
|
Ekter SA
AT:EKTER
|
0.073x |
|
Excel Industries Limited
NSE:EXCELINDUS
|
0.010x |
|
Burcelik Vana Sanayi ve Ticaret AS
IS:BURVA
|
-2.892x |
|
SHL Consolidated Bhd
KLSE:6017
|
0.026x |
|
CBO Territoria S.A.
PA:CBOT
|
0.039x |
Annual Cash Flow Conversion Efficiency for ADC Therapeutics SA (2017–2025)
The table below shows the annual cash flow conversion efficiency of ADC Therapeutics SA from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see ADC Therapeutics SA market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-185.83 Million | $-141.17 Million | 0.760x | +24.31% |
| 2024-12-31 | $-202.64 Million | $-123.83 Million | 0.611x | -23.67% |
| 2023-12-31 | $-148.25 Million | $-118.69 Million | 0.801x | +145.99% |
| 2022-12-31 | $79.45 Million | $-138.31 Million | -1.741x | -23.89% |
| 2021-12-31 | $166.09 Million | $-233.38 Million | -1.405x | -179.40% |
| 2020-12-31 | $335.50 Million | $-168.73 Million | -0.503x | +54.02% |
| 2019-12-31 | $111.16 Million | $-121.58 Million | -1.094x | -13.78% |
| 2018-12-31 | $126.24 Million | $-121.36 Million | -0.961x | -219.61% |
| 2017-12-31 | $249.17 Million | $-74.94 Million | -0.301x | -- |
About ADC Therapeutics SA
ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatme… Read more